Navigation Links
BioVex Raises $40 Million in First Close of Series F Financing
Date:3/30/2009

WOBURN, Mass., March 30 /PRNewswire/ -- BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today it has raised $40 million in the first close of a series F private financing.

The placement was led by Forbion Capital Partners, who were joined by other existing investors including Credit Agricole Private Equity, Harris & Harris Group, Innoven Partners, New Science Ventures, Triathlon Medical Venture Partners and Scottish Equity Partners.

Philip Astley-Sparke, President & CEO for BioVex Inc said:

"Following the unprecedented number of durable complete remissions generated with our lead cancer product, OncoVEX GM-CSF in a Phase II study in metastatic melanoma, the funds will be used to commence a pivotal Phase III study. The Board is currently examining a number of options to raise a further $20 million to fund preparations for a BLA filing following the generation of Phase III data in 2010."

The Phase III study design agreed with the FDA under a Special Protocol Assessment (SPA) follows directly from the study design successfully employed in Phase II. The Phase III study will also enroll previously treated patients with unresectable Stage IIIc and Stage IV disease using OncoVEX GM-CSF as monotherapy. Stage IIIb patients will also be eligible. The primary efficacy endpoint will also be response rate-based; the primary objective being to demonstrate a statistically significant increase in the rate of objective responses maintained for six months or more, in comparison to control therapy (subcutaneously administered GM-CSF). The study is intended to enroll 360 evaluable patients randomized such that 240 patients receive OncoVEX GM-CSF and 120 patients receive control. BioVex plans to begin enrolling patients for the Phase III study in the second quarter of 2009.

About OncoVEX GM-CSF Phase II Clinical Trial

BioVex recently concluded a 50-patient Phase II trial for OncoVEX GM-CSF as a standalone therapy in patients with unresectable Stage IIIc and Stage IV metastatic melanoma. The trial was designed to measure overall objective response, which is defined as a complete response (CR), where disease is completely eliminated, or partial response (PR), where there is a >50% reduction in disease burden. 87% of patients who entered the study were progressing after having failed prior therapy. 13 objective systemic responses (26% objective response rate) were achieved including eight CRs. Eleven responses have so far continued for more than 6 months (range 5-28+ months). Responses were observed in patients with all stages of disease, including the complete resolution of un-injected visceral deposits.

About BioVex

BioVex is a privately held biotechnology company based in Woburn, MA. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

The Company's lead cancer technology platform, OncoVEX GM-CSF is a first-in-class oncolytic, or cancer destroying virus technology. OncoVEX GM-CSF works by: replicating and spreading within solid tumors, causing the death of cancer cells; while stimulating the immune system to destroy un-injected metastatic deposits. Both modes of action have been clearly validated in the clinic, where multiple patients with metastatic disease progressing at enrollment have been declared disease free. BioVex believes OncoVEX GM-CSF has the potential to become a leading standard of care in the treatment of many solid tumors based on the strength of clinical data generated to date, coupled with a benign side effect profile.

The Company's second program is a vaccine for genital herpes, ImmunoVEX HSV2, which provides complete protection in animal models of the disease. The vaccine has been authorized to commence clinical testing in the UK.

For further information, please go to www.biovex.com.


'/>"/>
SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioVex to Present at the UBS Global Life Sciences Conference
2. BioVex Closes Second Round of Series E Financing
3. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
4. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
5. Moodys Raises Boston Scientifics Rating Outlook to Stable
6. GlycoVaxyn AG Raises CHF 25 Million in Financing Led by Edmond de Rothschild Investment Partners
7. Eiger BioPharmaceuticals Raises $7.1 Million A Round
8. NanoBio Corporation Raises $12 Million in Series B Financing
9. Divergence Raises $11.8 Million in Series C Financing
10. Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009.
11. AMERIGROUP Praises Expansion of State Childrens Health Insurance Program (SCHIP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... BARBARA, CALIFORNIA (PRWEB) , ... October 10, 2017 ... ... management, technological innovation and business process optimization firm for the life sciences and ... BoxWorks conference in San Francisco. , The presentation, “Automating GxP Validation ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting in ... professor in Harvard University’s Departments of Physics and Astronomy, has been selected for membership ... the winning team for the 2015 Breakthrough Prize in Fundamental physics for the discovery ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available ... bioinformatics software to perform Hi-C metagenome deconvolution using their own facilities, supplementing ...
(Date:10/5/2017)... , ... October 05, 2017 , ... LabRoots , ... scientists from around the world, is giving back to cancer research with a month-long ... , Now through October 31, shoppers can use promo code PinkRibbon to get ...
Breaking Biology Technology:
(Date:10/4/2017)... Oct. 4, 2017  GCE Solutions, a global clinical research organization ... document anonymization solution on October 4, 2017. Shadow is designed to ... comply with policy 0070 of the European Medicines Agency (EMA) in ... ... ...
(Date:6/30/2017)... , June 30, 2017 Today, American ... and supplier of face and eye tracking software, ... Product provider program. "Artificial intelligence ... way to monitor a driver,s attentiveness levels while ... being able to detect fatigue and prevent potential ...
(Date:5/16/2017)... TEANECK, N.J. , May 16, 2017  Veratad ... leading provider of online age and identity verification solutions, ... the K(NO)W Identity Conference 2017, May 15 thru May ... Ronald Regan Building and International Trade Center. ... across the globe and in today,s quickly evolving digital ...
Breaking Biology News(10 mins):